Divis Laboratories Intrinsic Value
DIVISLAB • Healthcare
Current Stock Price
₹5850.00
Primary Intrinsic Value
₹2285.36
Market Cap
₹310.1K Cr
-50.5%
Downside
Median Value
₹2895.50
Value Range
₹1755 - ₹7796
Assessment
Trading Above Calculated Value
Safety Margin
-100.0%
DIVISLAB Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹2285.36 | ₹1828.29 - ₹2742.43 | -60.9% | EPS: ₹103.88, Sector P/E: 22x |
| Book Value Method | asset | ₹5648.68 | ₹5083.81 - ₹6213.55 | -3.4% | Book Value/Share: ₹2824.34, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹4316.98 | ₹3885.28 - ₹4748.68 | -26.2% | Revenue/Share: ₹2158.49, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹7796.23 | ₹7016.61 - ₹8575.85 | +33.3% | EBITDA: ₹4132.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2895.50 | ₹2316.40 - ₹3474.60 | -50.5% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹1755.00 | ₹1579.50 - ₹1930.50 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1755.00 | ₹1579.50 - ₹1930.50 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹7280.00 | ₹6552.00 - ₹8008.00 | +24.4% | ROE: 18.4%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹2569.31 | ₹2312.38 - ₹2826.24 | -56.1% | EPS: ₹103.88, BVPS: ₹2824.34 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
DIVISLAB Intrinsic Value Analysis
What is the intrinsic value of DIVISLAB?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Divis Laboratories (DIVISLAB) is ₹2895.50 (median value). With the current market price of ₹5850.00, this represents a -50.5% variance from our estimated fair value.
The valuation range spans from ₹1755.00 to ₹7796.23, indicating ₹1755.00 - ₹7796.23.
Is DIVISLAB undervalued or overvalued?
Based on our multi-method analysis, Divis Laboratories (DIVISLAB) appears to be trading above calculated value by approximately 50.5%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 19.73 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 18.4% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 33.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.68x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Divis Laboratories
Additional stock information and data for DIVISLAB
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1,653 Cr | ₹1,251 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1,261 Cr | ₹1,127 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹2,460 Cr | ₹1,106 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹1,912 Cr | ₹815 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹1,947 Cr | ₹1,947 Cr | Positive Free Cash Flow | 8/10 |